Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Oct 2008

Racila Emilian, Link Brian K, Weng Wen-Kai, Witzig Thomas E, Ansell Stephen, Maurer Matthew J, Huang Jian, Dahle Christopher, Halwani Ahmad, Levy Ronald, Weiner George J

Abstract excerpt

PURPOSE: Complement may play a role in the clinical response to rituximab and other monoclonal antibody-based therapies of cancer. The purpose of this study was to explore the relationship between the C1qA([276]) polymorphism and the clinical response to rituximab in patients with follicular lymp...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement C1q

Share to Lymphoma, B-Cell

Share to Lymphoma, Follicular

Share to Lymphoma, Large B-Cell, Diffuse

Share to Remission Induction

Share to Rituximab

Source

Open in PubMed Open full text

Identifiers

PMID: 18927313
DOI: 10.1158/1078-0432.CCR-08-0745
PMCID: PMC2907116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18927313-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.PMID 18927313Read ↗

FCGR3A polymorphism : It is helpful for the management of diffuse large B-cell lymphomaSemantic proximity Read ↗

The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement.Semantic proximity Read ↗

Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.Semantic proximity Read ↗

Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.Semantic proximity Read ↗

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.Semantic proximity Read ↗

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.Semantic proximity Read ↗

Polymorphisms in complement system genes and risk of non-Hodgkin lymphoma.Semantic proximity Read ↗

A regulatory variant in the C1Q gene cluster is associated with tuberculosis susceptibility and C1qA plasma levels in a South African population.Semantic proximity Read ↗

Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger.Semantic proximity Read ↗

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.Semantic proximity Read ↗

Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma.Semantic proximity Read ↗

Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.